ArticleJournal of hematology2025

Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program.

Ingrid Blydt-Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.